Pulmonary Arterial Hypertension News and Research

RSS
Pulmonary arterial hypertension (PAH) is a condition involving high blood pressure and structural changes in the walls of the pulmonary arteries, which are the blood vessels that connect the right side of the heart to the lungs. Affecting people of all ages and ethnic backgrounds - but most commonly found in young women of child-bearing years - the disease has historically been chronic and incurable, with a poor survival rate. PAH is often not diagnosed in a timely manner because its early symptoms can be confused with those of many other pulmonary and respiratory conditions. Symptoms include shortness of breath, extreme fatigue, dizziness, fainting, swollen ankles and legs and chest pain (especially during physical activity). With proper diagnosis, there are currently several therapies to alleviate symptoms and improve quality of life for PAH patients. The key is to find a PAH specialist and pursue immediate treatment.
Cedars-Sinai receives $7.3 million grant to test safety of novel cell-based therapy in treating PAH

Cedars-Sinai receives $7.3 million grant to test safety of novel cell-based therapy in treating PAH

No added benefit proven for pulmonary arterial hypertension drug, IQWiG finds

No added benefit proven for pulmonary arterial hypertension drug, IQWiG finds

New report reveals prescription medication costs may increase up to 13% in 2016

New report reveals prescription medication costs may increase up to 13% in 2016

European Commission approves extended indication for Amgen's Kyprolis (carfilzomib) for the treatment of relapsed multiple myeloma patients

European Commission approves extended indication for Amgen's Kyprolis (carfilzomib) for the treatment of relapsed multiple myeloma patients

Circulating angiogenic factor shows PAH biomarker potential

Circulating angiogenic factor shows PAH biomarker potential

New blood test could help predict severity of pulmonary arterial hypertension

New blood test could help predict severity of pulmonary arterial hypertension

Potential non-invasive screening biomarker for SSc-PAH

Potential non-invasive screening biomarker for SSc-PAH

Right ventricular echocardiography predicts targeted therapy outcome in PAH

Right ventricular echocardiography predicts targeted therapy outcome in PAH

Reduced RV functional reserve may explain poor SSc-PAH outcomes

Reduced RV functional reserve may explain poor SSc-PAH outcomes

Elevated endothelial progenitor cells may characterise PAH patients

Elevated endothelial progenitor cells may characterise PAH patients

Pulmonary hypertension impacts walking ability in SSc patients

Pulmonary hypertension impacts walking ability in SSc patients

More evidence for combination therapy benefits in PAH

More evidence for combination therapy benefits in PAH

Detailed digital models of human organs could bring substantial benefits to clinical trials

Detailed digital models of human organs could bring substantial benefits to clinical trials

Novel gene therapy can treat pulmonary hypertension linked with heart failure

Novel gene therapy can treat pulmonary hypertension linked with heart failure

Meta-analysis supports combination therapy for PAH patients

Meta-analysis supports combination therapy for PAH patients

Minimally important dyspnoea, fatigue changes in PAH patients defined

Minimally important dyspnoea, fatigue changes in PAH patients defined

Increased BMP7 levels predict PAH mortality

Increased BMP7 levels predict PAH mortality

BMPR2 mutations affect outcomes of PAH patients

BMPR2 mutations affect outcomes of PAH patients

Tricuspid regurgitation tied to outcomes in PAH patients

Tricuspid regurgitation tied to outcomes in PAH patients

Regulatory immune cells compromised in PAH

Regulatory immune cells compromised in PAH